Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis (Q33432063)

26 July 2017

1 reference

title

Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis (English)

1 reference

26 July 2017

main subject

organ transplantation

1 reference

1 reference

C3 glomerulonephritis

1 reference

1

Lindsay S Keir

1 reference

26 July 2017

Craig B Langman

2

1 reference

26 July 2017

publication date

25 April 2016

1 reference

Transfusion and Apheresis Science

26 July 2017

published in

1 reference

26 July 2017

volume

54

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

203-211

1 reference

Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

The molecular biology of thrombotic microangiopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Pathogenesis of thrombotic microangiopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Thrombotic microangiopathy and associated renal disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Thrombotic microangiopathic haemolytic anaemia (thrombotic microangiopathy)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Atypical hemolytic-uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Syndromes of thrombotic microangiopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

The various states of von Willebrand factor and their function in physiology and pathophysiology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Complement cascade in systemic lupus erythematosus: analyses of the three activation pathways.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Complement genetics, deficiencies, and disease associations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Treatment options for HUS secondary to Escherichia coli O157:H7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Shiga toxin in enterohemorrhagic E.coli: regulation and novel anti-virulence strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Differential binding of Shiga toxin 2 to human and murine neutrophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Shiga toxin binds to activated platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Identification of TLR4 as the receptor that recognizes Shiga toxins in human neutrophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Globotriaosyl ceramide receptor function - where membrane structure and pathology intersect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Shiga Toxins Activate the NLRP3 Inflammasome Pathway To Promote Both Production of the Proinflammatory Cytokine Interleukin-1β and Apoptotic Cell Death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Increased advanced oxidation of protein products and enhanced total antioxidant capacity in plasma by action of toxins of Escherichia coli STEC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Microparticle generation and leucocyte death in Shiga toxin-mediated HUS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Diagnosis of complement alternative pathway disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Eculizumab in severe Shiga-toxin-associated HUS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Long-term outcomes of Shiga toxin hemolytic uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Treatment of typical hemolytic-uremic syndrome. Knowledge gained from analyses of the 2011 E. coli outbreak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Safe and effective use of eculizumab in the treatment of severe Shiga toxin Escherichia coli-associated hemolytic uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

The role of complement in C3 glomerulopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Anti-factor B autoantibody in dense deposit disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Disruption of disulfide bonds is responsible for impaired secretion in human complement factor H deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Regulating complement in the kidney: insights from CFHR5 nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Complement factor H related proteins (CFHRs)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

C3 glomerulopathy: consensus report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Eculizumab for treatment of rapidly progressive C3 glomerulopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Eculizumab in Pediatric Dense Deposit Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

A case of C3 glomerulonephritis successfully treated with eculizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Timing of eculizumab therapy for C3 glomerulonephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Eculizumab in the treatment of membranoproliferative glomerulonephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Rituximab fails where eculizumab restores renal function in C3nef-related DDD

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Treatment of C3 glomerulopathy with complement blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Update on Streptococcus pneumoniae associated hemolytic uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

De novo thrombotic microangiopathy after non-renal solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2016.04.010

10.1016/J.TRANSCI.2016.04.010

7 January 2021

Identifiers

DOI

1 reference

26 July 2017

1 reference